Pnc Financial Services Group, Inc. Nektar Therapeutics Transaction History

Pnc Financial Services Group, Inc.

$148 Billion
Q4 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.42 - $0.57 $42 - $56	100 New	100 $0
Q2 2023 Aug 11, 2023	BUY	$0.53 - $1.03 $19 - $38	37 Added 10.6%	386 $0
Q1 2023 May 15, 2023	SELL	$0.64 - $3.15 $1,205 - $5,931	-1,883 Reduced 84.36%	349 $0
Q4 2022 Feb 10, 2023	SELL	$2.03 - $4.28 $34,913 - $73,611	-17,199 Reduced 88.51%	2,232 $5,000
Q3 2022 Nov 10, 2022	BUY	$3.04 - $5.14 $35,130 - $59,397	11,556 Added 146.74%	19,431 $62,000
Q2 2022 Aug 12, 2022	BUY	$3.17 - $6.17 $1,987 - $3,868	627 Added 8.65%	7,875 $29,000
Q1 2022 May 12, 2022	SELL	$4.16 - $13.72 $11,265 - $37,153	-2,708 Reduced 27.2%	7,248 $39,000
Q4 2021 Feb 11, 2022	BUY	$10.83 - $18.41 $40,450 - $68,761	3,735 Added 60.04%	9,956 $134,000
Q3 2021 Nov 05, 2021	BUY	$13.07 - $18.84 $3,045 - $4,389	233 Added 3.89%	6,221 $111,000
Q2 2021 Aug 06, 2021	SELL	$16.52 - $20.4 $1,569 - $1,937	-95 Reduced 1.56%	5,988 $102,000
Q1 2021 May 07, 2021	BUY	$16.56 - $25.46 $16,725 - $25,714	1,010 Added 19.91%	6,083 $121,000
Q4 2020 Feb 12, 2021	BUY	$15.77 - $19.03 $1,592 - $1,922	101 Added 2.03%	5,073 $86,000
Q3 2020 Nov 06, 2020	SELL	$16.59 - $24.79 $56,505 - $84,434	-3,406 Reduced 40.65%	4,972 $82,000
Q2 2020 Aug 07, 2020	SELL	$16.86 - $23.44 $590 - $820	-35 Reduced 0.42%	8,378 $194,000
Q1 2020 May 08, 2020	SELL	$14.47 - $27.96 $97,122 - $187,667	-6,712 Reduced 44.38%	8,413 $150,000
Q4 2019 Feb 07, 2020	BUY	$15.87 - $23.12 $66,479 - $96,849	4,189 Added 38.3%	15,125 $326,000
Q3 2019 Nov 08, 2019	SELL	$16.91 - $36.27 $236,418 - $507,090	-13,981 Reduced 56.11%	10,936 $199,000
Q2 2019 Aug 09, 2019	BUY	$31.0 - $36.3 $429,071 - $502,428	13,841 Added 124.96%	24,917 $0
Q1 2019 May 10, 2019	SELL	$31.58 - $46.35 $6,379 - $9,362	-202 Reduced 1.79%	11,076 $0
Q4 2018 Feb 08, 2019	BUY	$30.43 - $56.65 $13,723 - $25,549	451 Added 4.17%	11,278 $370,000
Q3 2018 Nov 09, 2018	SELL	$46.46 - $68.49 $136,174 - $200,744	-2,931 Reduced 21.3%	10,827 $0
Q2 2018 Aug 10, 2018	SELL	$46.25 - $104.45 $1.26 Million - $2.85 Million	-27,308 Reduced 66.5%	13,758 $0
Q1 2018 May 11, 2018	SELL	$57.4 - $108.44 $474,353 - $896,148	-8,264 Reduced 16.75%	41,066 $0
Q4 2017 Feb 09, 2018	BUY	$23.02 - $60.5 $432,614 - $1.14 Million	18,793 Added 61.54%	49,330 $0
Q3 2017 Nov 13, 2017	BUY	$17.79 - $24.0 $543,253 - $732,888	30,537	30,537 $0

Others Institutions Holding NKTR

# of Institutions

152

Shares Held

131M

Call Options Held

92.7K

Put Options Held

4.9K

Black Rock Inc. New York, NY

15.2M
Shares

$14.1 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

12.3M
Shares

$11.5 Million
0.0% of portfolio
Samlyn Capital, LLC New York, NY

9.67M
Shares

$8.99 Million
0.14% of portfolio
Nantahala Capital Management, LLC New Canaan, CT

7.81M
Shares

$7.26 Million
0.37% of portfolio
Acadian Asset Management LLC Boston, MA

7.2M
Shares

$6.7 Million
0.02% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.

Account